Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders

Brain Research

Volumn 738, Issue 2, 1996, Pages 265-274

  Loeffler, D A ^a   LeWitt, P A ^a,b   Juneau, P L ^a   Sima, A A F ^b   Nguyen, H U ^a   DeMaggio, A J ^a   Brickman, C M ^a   Brewer, G J ^c   Dick, R D ^c   Troyer, M D ^d   Kanaley, L ^e  

^a SINAI GRACE HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e MCLEAN HOSPITAL   (United States)

Author keywords

acute phase protein; Alzheimer's disease; ceruloplasmin; copper; Huntington's disease; Parkinson's disease; progressive supranuclear palsy

Indexed keywords

ACUTE PHASE PROTEIN; CERULOPLASMIN; COPPER;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; IMMUNOCYTOCHEMISTRY; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; CASE-CONTROL STUDIES; CELL COUNT; CERULOPLASMIN; COPPER; HIPPOCAMPUS; HUMANS; HUNTINGTON DISEASE; MIDDLE AGED; NERVE DEGENERATION; NEURONS; PARKINSON DISEASE; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 0030569306     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(96)00782-2     Document Type: Article

References (82)

1. 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease, Cell, 52 (1988) 487-501.
2. [2] Aldred, A.R., Grimes, A., Schreiber, G. and Mercer, J.F.B., Rat ceruloplasmin: molecular cloning and gene expression in liver, choroid plexus, yolk sac, placenta, and testis, J. Biol. Chem., 262 (1987) 2875-2878.
3. [3] Bannister, J.V., Bannister, W.H., Hill, H.A.O., Mahood, J.F, Wilson, R.L. and Wolfden, B.S., Does ceruloplasmin dismute superoxide? No, FEBS Lett., 118 (1980) 127-129.
4. 2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices, FEBS Lett., 285 (1991) 111-114.
5. [5] Baumann, H. and Gauldie, J., Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation, Mol. Biol. Med., 7 (1990) 147-159.
6. [6] Brewer, G.J., Dick, R.D., Yuzbasiyan-Gurkin, V., Tankanow, R., Young, A.B. and Kluin, K.J., Initial therapy of patients with Wilson's disease with tetrathiomolybdate, Arch. Neurol., 48 (1991), 42-47.
7. [7] Brewer, G.J. and Yuzbasiyan-Gurkan, V., Wilson Disease, Medicine, 71 (1992) 139-164.
8. [8] Calabrese, L. and Carbonaro, M., An e.p.r. study of the non-equivalence of the copper sites of caeruloplasmin, Biochem. J., 238 (1986) 291-295.
9. [9] Chutkow, J., Evidence for uptake of nonceruloplasmin copper in the brain: effect of ionic copper and amino acids, Proc. Soc. Exp. Biol. Med., 158 (1978) 113-116.
10. [10] Cohen, G., The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence, J. Neural Transm., Suppl. 19 (1983) 89-103.
11. [11] Colton, T., Statistics in Medicine, Little & Brown, Boston, 1974, p. 207.
12. [12] Connor, J.R., Snyder, B.S., Beard, J.L., Fine, R.E. and Mufson, E.J., Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease, J. Neurosci. Res., 31 (1992) 327-335.
13. [13] Connor, J.R., Tucker, P., Johnson, M. and Snyder, B. Ceruloplasmin levels in the human superior temporal gyrus in aging and Alzheimer's disease, Neurosci. Lett., 159 (1993) 88-90.
14. [14] Coria, F., Casano, E., Prelli, F., Larrondo-Lillo, M., Van Duinen, S., Shelanski, M.L. and Frangione, B., Isolation and characterization of amyloid P component from Alzheimer's disease and other cerebral amyloidosis, Lab. Invest., 58 (1988) 454-458.
15. [15] Del Principe, D., Menichelli, A. and Colistra, C., The ceruloplasmin and transferrin system in cerebrospinal fluid of acute leukemia patients, Acta Paediat. Scand., 78 (1989) 327-328.
16. [16] Dexter, D.T., Carter, C., Wells, F.R., Javoy-Agid, F., Agid, Y., Lees, A., Jenner, P. and Marsden, C.D., Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease, J. Neurochem., 52 (1989) 881-889.
17. [17] Dexter, D.T., Wells, F.R., Lees, A.J., Agid, F., Agid, Y., Jenner, P. and Marsden, C.D., Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease, J. Neurochem., 52 (1989) 1830-1836.
18. [18] Eikelenboom, P. and Stam, F.C., Immunoglobulins and complement factors in senile plaques, Acta Neuropathol., 57 (1982) 239-242.
19. [19] Evans, P.M., Alzheimer's senile dementia: a radical case of cephaloconiosis, Neurobiol. Aging, 9 (1988) 225-226.
20. [20] Fahn, S. and Cohen, G., The oxidant stress hypothesis in Parkinson's disease: evidence supporting it, Ann. Neurol., 32 (1992) 804-812.
21. [21] Friedlich, A.L. and Butcher, L.L., Involvement of free oxygen radicals in β-amyloidosis: an hypothesis, Neurobiol. Aging, 15 (1994) 443-455.
22. [22] Fleming, R.E. and Gitlin, J.D., Primary structure of rat ceruloplasmin and analysis of tissue-specific gene expression during development, J. Biol. Chem., 265 (1990) 7701-7707.
23. [23] Folkman, J. and Klagsburn, M., Angiogenic factors, Science, 235 (1987) 442-447.
24. [24] Gitlin, J.D., Gitlin, J.I. and Gitlin, D., Localizing of C-reactive protein in synovium of patients with rheumatoid arthritis, Arth. Rheum., 20 (1977) 1491-1499.
25. [25] Goldstein, I.M., Kaplan, H.B., Edelson, H.S. and Weissman, G., Ceruloplasmin, a scavenger of superoxide anion radicals, J. Biol. Chem., 254 (1979) 4040-4045.
26. [26] Good, P.F., Perl, D.P., Bierer, L.M. and Schmeidler, J., Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's Disease: a laser microprobe (LAMMA) study, Ann. Neurol., 31 (1992) 286-292.
27. [27] Graham, D.G., Tiffany, S.M., Bell, W.R. and Gutnecht, W.F., Autooxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-OHDA and related compounds towards C1300 neuroblastoma cells in vitro, Mol. Pharmacol., 1 (1978) 644-653.
28. [28] Griffin, W.S.T., Stanley, L.C., Ling, C., White, L., MacLeod, V., Perrot, L.J., White, C.L. III, and Araoz, C., Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease, Proc. Natl. Acad. Sci. USA, 86 (1989) 7611-7615.
29. [29] Gutteridge, J.M.C., Plasma ascorbate levels and inhibition of the antioxidant activity of caeruloplasmin, Clin. Sci., 81 (1991) 413-417.
30. [30] Gutteridge, J.M.C. and Stocks, J., Caeruloplasmin: physiological and pathological perspectives, CRC Crit. Rev. Clin. Lab. Sci., 14 (1981) 257-329.
31. [31] Hancock, M.B., Visualization of peptide-immunoreactive processes of serotonin-immunoreactive cells using two color immunoperoxidase staining, J. Histochem. Cytochem., 32 (1984) 311-314.
32. [32] Harris, E.D., The transport of copper, Prog. Clin. Biol. Res., 380 (1993) 163-179.
33. [33] Harris, Z.L., Takahashi, Y., Miyajima, H., Serizawa, M., MacGillvray, R.T.A. and Gitlin, J.D., Aceruloplasminemia: molecular characterization of this disorder of iron metabolism, Proc. Natl. Acad. Sci. USA, 92 (1995) 2539-2543.
34. [34] Hsu, S.-M., Raine, L. and Fanger, H., Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures, J. Histochem. Cytochem., 29 (1981) 577-580.
35. [35] Huebers, H.A. and Finch, C.A., The physiology of transferrin and transferrin receptors, Physiol. Rev., 67 (1987) 520-582.
36. [36] Jaeger, J.L., Shimizu, N. and Gitlin, J.D., Tissue-specific ceruloplasmin gene expression in the mammary gland, Biochem. J., 280 (1991) 671-677.
37. [37] Jamieson, D., Oxygen toxicity and reactive oxygen metabolites in mammals, Free Radical Biol. Med., 7 (1989) 87-109.
38. [38] Kalaria, R.N., Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease, Res. Immunol., 143 (1992) 637-641.
39. [39] Linder, M.C. and Moor, J.R., Plasma ceruloplasmin: evidence for its presence in and uptake by heart and other organs of the rat, Biochim. Biophys. Acta, 499 (1977) 329-336.
40. [40] Loeffler, D.A., Connor, J.R., Juneau, P.L., Snyder, B.S., Kanaley, L., DeMaggio, A.J., Nguyen, H., Brickman, C.M. and LeWitt, P.A., Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions, J. Neurochem., 65 (1995) 710-716.
41. [41] Loeffler, D.A., DeMaggio, A.J., Juneau, P.L., Brickman, C.M., Mashour, G.A., Finkelman, J.H., Pomara, N. and LeWitt, P.A., Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease. Alzheimer's Dis. Assoc. Disord., 8 (1994) 190-197.
42. [42] Logan, J.I., Harveyson, K.B., Wisdom, G.B., Hughes, A.E. and Archbold, G.P.R., Hereditary caeruloplasmin deficiency, dementia and diabetes mellitus, Q. J. Med., 87 (1994) 663-670.
43. [43] Lovell, M.A., Ehmann, W.D., Butler, S.M. and Markesbery, W.R., Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease, Neurology,, 45 (1995) 1594-1601.
44. [44] McGeer, P.L., Itagaki, S., Boyes, B.E. and McGeer, E.G., Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains, Neurology, 38 (1988) 1285-1291.
45. [45] Mecocci, P., MacGarvey, U. and Beal, M.F., Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease, Ann. Neurol., 36 (1994) 747-751.
46. [46] Montgomery, D.C., Design and Analysis of Experiments, 2nd edn., Wiley and Sons, Toronto, 1984, pp. 69-70.
47. [47] Moshkov, K.A., Lakatos, S., Hajdu, J., Zavodszky, P. and Neifakh, S.A., Proteolysis of human ceruloplasmin. Some peptide bonds are particularly susceptible to proteolytic attack, Eur. J. Biochem., 94 (1979) 127-134.
48. [48] Musci, G., Bonaccorsi di Patti, M.C., Fagiolo, U. and Calabrese, L., Age-related changes in human ceruloplasmin. Evidence for oxidative modifications, J. Biol. Chem., 268 (1993) 13388-13395.
49. [49] Nalbandyan, R.N., Copper in brain, Neurochem. Res., 8 (1983) 1211-1232.
50. [50] Nixon, R.A. and Cataldo, A.M. (1994), Free radicals, proteolysis, and the degeneration of neurons in Alzheimer disease: how essential is the β-amyloid link? Neurabiol. Aging, 15 (1994) 463-469.
51. [51] Osaki, S., Johnson, D.A. and Frieden, E., The possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum, J. Biol. Chem., 241 (1966) 2746-2751.
52. [52] Patel, B.N.C. and David, S., Expression of ceruloplasmin by astrocytes and its modulation by cytokines, Proc. Soc. Neurosci., 21 (1995), 564.
53. [53] Prohaska, J.R., Functions of trace elements in brain metabolism, Physiol. Rev., 67 (1987) 858-901.
54. [54] Riederer, P., Sofic, E., Rausch, W.D., Schmidt, B., Reynolds, G.P., Jellinger, K. and Youdim, M.B.H., Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains, J. Neurochem., 52 (1989) 515-520.
55. [55] Samokyszyn, V.M., Miller, D.M., Reif, D.W. and Aust, S.D., Inhibition of superoxide and ferritin-dependent lipid peroxidation by ceruloplasmin, J. Biol. Chem., 264 (1989) 21-26.
56. [56] SAS Institute. Inc., SAS/Stat User's Guide, Version 6, 4th edn., vol. 2, SAS Institute Inc., Cary, NC, 1990, p. 1636.
57. [57] Schwartzman, A.L., Voronina, O.V., Gaitskhoki, V.S. and Patkin, E.L., Expression of ceruloplasmin gene in mammalian organs from the data of hybridization analysis with complementary DNA probes, Molek. Biol., 24 (1990) 657-662.
58. [58] Seitz, R.J. and Wechsler, W., Immunohistochemical demonstration of serum proteins in human cerebral gliomas, Acta Neuropathol. (Berl.), 73 (1987) 145-152.
59. [59] Sergeev, A.G., Pavlov, A.R., Revina, A.A. and Yaropolov, A.I., The mechanism of interaction of ceruloplasmin with superoxide radicals, Int. J. Biochem., 25 (1993) 1549-1554.
60. [60] Sharoyan, S.G.A., Shaljian, A.A., Nalbandyan, R.M. and Buniatian, H.C., Two copper-containing proteins from white and gray matter of brain, Biochim. Biophys. Acta. 493 (1977) 478-487.
61. [61] Snedecor, G.W. and Cochrane, W.G., Statistical Methods, 7th edn., Iowa State Univ Press. Ames, IA, 1980, p. 97.
62. [62] Southorn, P. and Powis, G., Free radicals in medicine. II. Involvement in human disease, Mayo Clin. Proc., 63 (1988) 390-408.
63. [63] Stocks, J., Gutteridge, J.M.C., Sharp, R.J. and Dormandy, T.L., The inhibition of lipid autoxidation by human serum and its relation to serum proteins and α-tocopherol. Clin. Sci. Mol. Med., 47 (1974) 223-233.
64. 2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients, Lab. Invest., 66 (1992) 223-230.
65. [65] Subbarao, K.V., Richardson, J.S. and Ang, L.C., Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro, J. Neurochem., 55 (1990) 342-345.
66. [66] Swaiman, K.F., Hallervorden-Spatz syndrome and brain iron metabolism, Arch. Neurol., 48 (1991) 1285-1293.
67. [67] Swain, J.A., Darley-Usmar, V. and Gutteridge, J.M.C., Peroxynitrite releases copper from caeruloplasmin: implications for atherosclerosis, FEBS Lett., 342 (1994) 49-52.
68. [68] Taylor, C.G. and Bray, T.M., Effect of hyperoxia on oxygen free radical defense enzymes in the lung of zinc-deficient rats, J. Nutr., 121 (1991) 460-466.
69. [69] Theil, E.C., Ferritin: structure, gene regulation, and cellular function in animals, plants and microorganisms, Annu. Rev. Biochem., 56 (1987) 289-315.
70. [70] Thomas, T. and Schreiber, G., The expression of genes coding for positive acute-phase proteins in the reproductive tract of the female rat. High levels of ceruloplasmin mRNA in the uterus. FEBS Lett., 243 (1989) 381-384.
71. [71] Tooyama, I., Kimura, H., Akiyama, H. and McGeer, P.L., Reactive microglia express class I and class II major histocompatibility complex antigens in Alzheimer's disease, Brain Res., 523 (1990) 273-280.
72. [72] Tukey, J.M., Exploratory Data Analysis. Limited preliminary edn., vol. 1, Addison-Wesley, Redding, MA, chap. 5, 1970.
73. [73] Uitti, R.J., Rajput, A.H., Rozdilsky, B., Bickis, M., Wollin, T. and Yuen, W.K., Regional metal concentrations in Parkinson's disease and control brains, Can. J. Neurol. Sci., 16 (1989) 310-314.
74. [74] Volicer, L. and Crino, P.B., Involvement of free radicals in dementia of the Alzheimer type: a hypothesis, Neurobiol. Aging, 11 (1990) 567-571.
75. [75] Walker, F.J. and Fay, P.J., Characterization of an interaction between protein C and ceruloplasmin, J. Biol. Chem., 265 (1990) 1834-1836.
76. [76] Wirth, P.L. and Linder, M.C., Distribution of copper among components of human serum, J. Natl. Cancer Inst., 75 (1985) 277-284.
77. 2-macroglobulin and C-reactive protein, Brain Res., 629 (1993) 245-252.
78. [78] Yamamoto, T. and Hirano, A., A comparative study of modified Bielschowsky, Bodian and thioflavin S stains on Alzheimer's tangles, Neuropathol. Appl. Neurobiol., 12 (1986) 3-9.
79. [79] Yang, F., Friedrichs, W.E., Cupples, R.L., Bonifacio, M.J., Sanford, J.A., Horton, W.A. and Bowman, B.H., Human ceruloplasmin. Tissue-specific expression of transcripts produced by alternative splicing, J. Biol. Chem., 265 (1989) 10780-10785.
80. [80] Yehuda, S. and Youdim, M.B.H., Brain iron deficiency: biochemistry and behavior, in M.B.H. Youdim (Ed.), Brain Iron, Neurochemical and Behavioral Aspects, Taylor and Francis, London, 1988, pp. 89-114.
81. [81] Zar, J.H., Biostatical Analysis, Prentice Hall, Englewood Cliffs, NJ, 1984, pp. 162-190.
82. [82] Zelman, F.P., Thienhaus, O.J. and Bosmann, H.B., Superoxide dismutase activity in Alzheimer's disease: possible mechanism for paired helical filament formation, Brain Res., 476 (1989) 160-162.